journal
MENU ▼
Read by QxMD icon Read
search

Transfusion Medicine and Hemotherapy

journal
https://www.readbyqxmd.com/read/27790081/regenerative-dentistry-animal-model-for-regenerative-endodontology
#1
Nisarat Ruangsawasdi, Matthias Zehnder, Raphael Patcas, Chafik Ghayor, Franz E Weber
BACKGROUND: Ectopic tissue has been observed frequently in human root canal specimens when cell homing studies were performed at the dorsum of rodents. In contrast, pulp-like tissue formed when immature teeth were implanted on top of the rat calvaria. It was surmised, yet not tested, that the implantation site might affect tissue ingrowth. METHODS: Four root sections from human immature molars cleaned with 5% sodium hypochlorite (NaOCl) followed by 17% ethylenediaminetetraacetic acid (EDTA) were implanted per rat (n = 5)...
September 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27781025/thrombopoietin-receptor-agonists-are-often-ineffective-in-immune-thrombocytopenia-and-or-cause-adverse-reactions-results-from-one-hand
#2
Fabian Depré, Nasra Aboud, Frauke Ringel, Abdulgabar Salama
BACKGROUND: Eltrombopag and romiplostim are thrombopoietin receptor agonists (TPOs) that have been increasingly used for the treatment of immune thrombocytopenia (ITP). Based on our experience, the incidence of abortive treatment with these drugs and the occurrence of adverse reactions that lead to therapy break-off despite response are higher than has been previously suggested. METHODS: During the last 8 years, a total of 65 patients were treated with eltrombopag and/or romiplostim at our institute...
September 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27781024/safety-of-factor-xiii-concentrate-analysis-of-more-than-20-years-of-pharmacovigilance-data
#3
Cristina Solomon, Wolfgang Korte, Dietmar Fries, Inna Pendrak, Christine Joch, Albrecht Gröner, Ingvild Birschmann
BACKGROUND: Plasma-derived factor XIII (FXIII) concentrate is an effective treatment for FXIII deficiency. We describe adverse drug reactions (ADRs) reported during pharmacovigilance monitoring of Fibrogammin®/Corifact® and review published safety data. METHODS: Postmarketing safety reports recorded by CSL Behring from June 1993 to September 2013 were analyzed. Clinical studies published during the same period were also reviewed. RESULTS: Commercial data indicated that 1,653,450,333 IU FXIII concentrate were distributed over the review period, equivalent to 1,181,036 doses for a 70 kg patient...
September 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27781023/quality-assurance-in-biobanking-for-pre-clinical-research
#4
REVIEW
Daniel Simeon-Dubach, Steffen M Zeisberger, Simon P Hoerstrup
It is estimated that not less than USD 28 billion are spent each year in the USA alone on irreproducible pre-clinical research, which is not only a fundamental loss of investment and resources but also a strong inhibitor of efficiency for upstream processes regarding the translation towards clinical applications and therapies. The issues and cost of irreproducibility has mainly been published on pre-clinical research. In contrast to pre-clinical research, test material is often being transferred into humans in clinical research...
September 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27781022/about-atmps-sops-and-gmp-the-hurdles-to-produce-novel-skin-grafts-for-clinical-use
#5
REVIEW
Fabienne Hartmann-Fritsch, Daniela Marino, Ernst Reichmann
BACKGROUND: The treatment of severe full-thickness skin defects represents a significant and common clinical problem worldwide. A bio-engineered autologous skin substitute would significantly reduce the problems observed with today's gold standard. METHODS: Within 15 years of research, the Tissue Biology Research Unit of the University Children's Hospital Zurich has developed autologous tissue-engineered skin grafts based on collagen type I hydrogels. Those products are considered as advanced therapy medicinal products (ATMPs) and are routinely produced for clinical trials in a clean room facility following the guidelines for good manufacturing practice (GMP)...
September 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27781021/the-use-of-adipose-tissue-derived-progenitors-in-bone-tissue-engineering-a-review
#6
REVIEW
Indranil Bhattacharya, Chafik Ghayor, Franz E Weber
2500 years ago, Hippocrates realized that bone can heal without scaring. The natural healing potential of bone is, however, restricted to small defects. Extended bone defects caused by trauma or during tumor resections still pose a huge problem in orthopedics and cranio-maxillofacial surgery. Bone tissue engineering strategies using stem cells, growth factors, and scaffolds could overcome the problems with the treatment of extended bone defects. In this review, we give a short overview on bone tissue engineering with emphasis on the use of adipose tissue-derived stem cells and small molecules...
September 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27781020/stem-cells-in-functional-bladder-engineering
#7
REVIEW
Jakub Smolar, Souzan Salemi, Maya Horst, Tullio Sulser, Daniel Eberli
Conditions impairing bladder function in children and adults, such as myelomeningocele, posterior urethral valves, bladder exstrophy or spinal cord injury, often need urinary diversion or augmentation cystoplasty as when untreated they may cause severe bladder dysfunction and kidney failure. Currently, the gold standard therapy of end-stage bladder disease refractory to conservative management is enterocystoplasty, a surgical enlargement of the bladder with intestinal tissue. Despite providing functional improvement, enterocystoplasty is associated with significant long-term complications, such as recurrent urinary tract infections, metabolic abnormalities, stone formation, and malignancies...
September 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27781019/stem-cell-mediated-regeneration-of-the-adult-brain
#8
REVIEW
Sebastian Jessberger
Acute or chronic injury of the adult mammalian brain is often associated with persistent functional deficits as its potential for regeneration and capacity to rebuild lost neural structures is limited. However, the discovery that neural stem cells (NSCs) persist throughout life in discrete regions of the brain, novel approaches to induce the formation of neuronal and glial cells, and recently developed strategies to generate tissue for exogenous cell replacement strategies opened novel perspectives how to regenerate the adult brain...
September 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27781018/tissue-engineering-and-regenerative-medicine-new-initiatives-for-individual-treatment-offers
#9
EDITORIAL
Beat M Frey, Steffen M Zeisberger, Simon P Hoerstrup
No abstract text is available yet for this article.
September 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27721708/in-vivo-adsorption-of-isoagglutinins-with-incompatible-red-blood-cell-transfusion-in-stem-cell-transplant-recipients
#10
Rainer Moog
No abstract text is available yet for this article.
July 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27721707/extracellular-vesicles-from-red-blood-cell-products-induce-a-strong-pro-inflammatory-host-response-dependent-on-both-numbers-and-storage-duration
#11
Marleen Straat, Anita N Böing, Anita Tuip-De Boer, Rienk Nieuwland, Nicole P Juffermans
BACKGROUND: Transfusion of red blood cells (RBCs) is associated with adverse outcome, but the causative factor is unknown. Extracellular vesicles (EVs) have pro-inflammatory properties. We hypothesized that EVs released from both fresh and stored RBC products can induce a host inflammatory response in a dose-dependent manner. METHODS: Whole blood was incubated with supernatant from RBC units stored for different time periods, either containing (different numbers of) EVs or depleted from EVs...
July 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27721706/hemoglobin-threshold-for-blood-transfusion-in-a-pediatric-intensive-care-unit
#12
Madhuradhar Chegondi, Jun Sasaki, André Raszynski, Balagangadhar R Totapally
OBJECTIVE: To evaluate the hemoglobin threshold for red cell transfusion in children admitted to a pediatric intensive care unit (PICU). METHODS: Retrospective chart review study. Tertiary care PICU. Critically ill pediatric patients requiring blood transfusion. No intervention. RESULTS: We analyzed the charts of all children between 1 month and 21 years of age who received packed red blood cell (PRBC) transfusions during a 2-year period. The target patients were identified from our blood bank database...
July 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27721705/cardiovascular-regenerative-technologies-update-and-future-outlook
#13
Anna Mallone, Benedikt Weber, Simon P Hoerstrup
In the effort of improving treatment for cardiovascular disease (CVD), scientists struggle with the lack of the regenerative capacities of finally differentiated cardiovascular tissues. In this context, the advancements in regenerative medicine contributed to the development of cell-based therapies as well as macro- and micro-scale tissue-engineering technologies. The current experimental approaches focus on different regenerative strategies including a broad spectrum of techniques such as paracrine-based stimulation of autologous cardiac stem cells, mesenchymal cell injections, 3D microtissue culture techniques and vascular tissue-engineering methods...
July 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27721704/heart-valve-replacements-with-regenerative-capacity
#14
Petra E Dijkman, Emanuela S Fioretta, Laura Frese, Francesco S Pasqualini, Simon P Hoerstrup
The incidence of severe valvular dysfunctions (e.g., stenosis and insufficiency) is increasing, leading to over 300,000 valves implanted worldwide yearly. Clinically used heart valve replacements lack the capacity to grow, inherently requiring repetitive and high-risk surgical interventions during childhood. The aim of this review is to present how different tissue engineering strategies can overcome these limitations, providing innovative valve replacements that proved to be able to integrate and remodel in pre-clinical experiments and to have promising results in clinical studies...
July 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27721703/cardiac-regenerative-medicine-the-potential-of-a-new-generation-of-stem-cells
#15
REVIEW
Elena Cambria, Julia Steiger, Julia Günter, Annina Bopp, Petra Wolint, Simon P Hoerstrup, Maximilian Y Emmert
Cardiac stem cell therapy holds great potential to prompt myocardial regeneration in patients with ischemic heart disease. The selection of the most suitable cell type is pivotal for its successful application. Various cell types, including crude bone marrow mononuclear cells, skeletal myoblast, and hematopoietic and endothelial progenitors, have already advanced into the clinical arena based on promising results from different experimental and preclinical studies. However, most of these so-called first-generation cell types have failed to fully emulate the promising preclinical data in clinical trials, resulting in heterogeneous outcomes and a critical lack of translation...
July 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27721702/adipose-tissue-derived-stem-cells-in-regenerative-medicine
#16
Laura Frese, Petra E Dijkman, Simon P Hoerstrup
In regenerative medicine, adult stem cells are the most promising cell types for cell-based therapies. As a new source for multipotent stem cells, human adipose tissue has been introduced. These so called adipose tissue-derived stem cells (ADSCs) are considered to be ideal for application in regenerative therapies. Their main advantage over mesenchymal stem cells derived from other sources, e.g. from bone marrow, is that they can be easily and repeatable harvested using minimally invasive techniques with low morbidity...
July 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27721701/mesenchymal-stem-stromal-cells-in-regenerative-medicine-can-preconditioning-strategies-improve-therapeutic-efficacy
#17
Richard Schäfer, Gabriele Spohn, Patrick C Baer
Mesenchymal stem/stromal cells (MSCs) are becoming increasingly important for the development of cell therapeutics in regenerative medicine. Featuring immunomodulatory potential as well as secreting a variety of trophic factors, MSCs showed remarkable therapeutic effects in numerous preclinical disease models. However, sustainable translation of MSC therapies to the clinic is hampered by heterogeneity of MSCs and non-standardized in vitro culture technologies. Moreover, potent MSC therapeutics require MSCs with maximum regenerative capacity...
July 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27721700/hematopoietic-stem-cells-in-regenerative-medicine-astray-or-on-the-path
#18
Albrecht M Müller, Sascha Huppertz, Reinhard Henschler
Hematopoietic stem cells (HSCs) are the best characterized adult stem cells and the only stem cell type in routine clinical use. The concept of stem cell transplantation laid the foundations for the development of novel cell therapies within, and even outside, the hematopoietic system. Here, we report on the history of hematopoietic cell transplantation (HCT) and of HSC isolation, we briefly summarize the capabilities of HSCs to reconstitute the entire hemato/lymphoid cell system, and we assess current indications for HCT...
July 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27721699/stem-cell-factories-the-rebirth-of-tissue-engineering-and-regenerative-medicine
#19
Beat M Frey, Steffen M Zeisberger, Simon P Hoerstrup
No abstract text is available yet for this article.
July 2016: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/27403094/cross-sectional-guidelines-for-therapy-with-blood-components-and-plasma-derivatives-chapter-5-human-albumin-revised
#20
(no author information available yet)
Chapter 5 'Human Albumin' that was suspended on January 10, 2011 has been completed and updated in the present version.
May 2016: Transfusion Medicine and Hemotherapy
journal
journal
40445
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"